We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
Read MoreHide Full Article
Key Takeaways
FUL trades at 10.4X forward earnings, near the low end of its five-year valuation range.
H.B. Fuller raised fiscal 2026 earnings support with higher estimates, strong quarterly results and guidance.
FUL faces volume softness, raw-material inflation and leverage risks tied to the proposed AMS acquisition.
H.B. Fuller Company (FUL - Free Report) presents a familiar value-stock dilemma. The shares look inexpensive, earnings support has improved and the company is pushing into higher-margin medical markets.
The caution is equally real. Volume softness, raw-material inflation, supply disruptions and acquisition-related leverage make this more than a simple low-multiple story.
FUL Looks Cheap on Forward Earnings
FUL trades at 10.4X forward 12-month earnings, below the Zacks sub-industry at 22.12X, the Zacks sector at 13.23X and the S&P 500 at 21.14X.
That multiple is also near the bottom of its five-year range of 10.25X to 21.76X, with a five-year median of 15.15X. For value investors, that compression makes FUL worth revisiting.
Image Source: Zacks Investment Research
Avery Dennison Corporation (AVY - Free Report) gives investors another materials-science reference point tied to adhesive and labeling markets. RPM International Inc. (RPM - Free Report) offers a specialty coatings, sealants and building-products comparison for investors tracking applied-materials demand.
H.B. Fuller Has Earnings Support
The earnings picture has not broken down. The fiscal 2026 earnings estimate has moved 2.1% higher over the past four weeks, while the company’s latest quarter delivered positive sales and earnings surprises.
In the second quarter of fiscal 2026, H.B. Fuller reported adjusted earnings of $1.41 per share, up 19% year over year. Revenues rose 6% to $950.3 million, with organic growth of 2.6%.
Guidance also provides support. Management projects fiscal 2026 adjusted EBITDA of $650-$675 million and adjusted earnings of $4.60-$4.90 per share, excluding the proposed Advanced Medical Solutions acquisition.
The discount is not risk-free. Management’s fiscal 2026 framework includes low- to mid-single-digit volume declines in the second half, with consumer-linked flexible packaging still soft.
Automotive demand also remains weak across regions. That keeps H.B. Fuller dependent on pricing, mix and restructuring savings to defend margins.
Raw materials add another pressure point. Nearly 90% of raw materials were higher sequentially in the second quarter, and more than 50 force majeure events remained in place.
H.B. Fuller and the AMS Risk Tradeoff
The Advanced Medical Solutions deal strengthens the long-term story. The proposed acquisition expands H.B. Fuller’s exposure to procedure-driven medical markets and could improve mix, growth and margins.
The deal is valued at about £715 million and is expected to add roughly $300 million in annual revenues. H.B. Fuller also targets about $55 million in annual revenue and cost synergies by 2031.
The tradeoff is leverage and execution. Pro forma net leverage is expected to be roughly 4X at close, with a target return to 2.5X-3X within two years.
FUL Scores Point to a Mixed Buy Case
The bottom line is that FUL screens attractively, but it is not a clean growth acceleration story. The stock’s value case rests on a low multiple, improving estimates and margin execution, while the risk case rests on volumes, inflation and acquisition leverage.
It also has a VGM Score of A, Value Score of A and Momentum Score of A, which supports the view that the stock has favorable value and sentiment characteristics.
The Growth Score of C keeps the signal balanced. For cautious investors, FUL looks more like a selective value opportunity than a no-risk bargain.
View the Zacks #1 Rank List
Image: Bigstock
Is FUL Stock a Buy Now or a Value Trap for Cautious Investors?
Key Takeaways
H.B. Fuller Company (FUL - Free Report) presents a familiar value-stock dilemma. The shares look inexpensive, earnings support has improved and the company is pushing into higher-margin medical markets.
The caution is equally real. Volume softness, raw-material inflation, supply disruptions and acquisition-related leverage make this more than a simple low-multiple story.
FUL Looks Cheap on Forward Earnings
FUL trades at 10.4X forward 12-month earnings, below the Zacks sub-industry at 22.12X, the Zacks sector at 13.23X and the S&P 500 at 21.14X.
That multiple is also near the bottom of its five-year range of 10.25X to 21.76X, with a five-year median of 15.15X. For value investors, that compression makes FUL worth revisiting.
Image Source: Zacks Investment Research
Avery Dennison Corporation (AVY - Free Report) gives investors another materials-science reference point tied to adhesive and labeling markets. RPM International Inc. (RPM - Free Report) offers a specialty coatings, sealants and building-products comparison for investors tracking applied-materials demand.
H.B. Fuller Has Earnings Support
The earnings picture has not broken down. The fiscal 2026 earnings estimate has moved 2.1% higher over the past four weeks, while the company’s latest quarter delivered positive sales and earnings surprises.
In the second quarter of fiscal 2026, H.B. Fuller reported adjusted earnings of $1.41 per share, up 19% year over year. Revenues rose 6% to $950.3 million, with organic growth of 2.6%.
Guidance also provides support. Management projects fiscal 2026 adjusted EBITDA of $650-$675 million and adjusted earnings of $4.60-$4.90 per share, excluding the proposed Advanced Medical Solutions acquisition.
H. B. Fuller Company Price and Consensus
H. B. Fuller Company price-consensus-chart | H. B. Fuller Company Quote
Why FUL Is Not a Clean Value Story
The discount is not risk-free. Management’s fiscal 2026 framework includes low- to mid-single-digit volume declines in the second half, with consumer-linked flexible packaging still soft.
Automotive demand also remains weak across regions. That keeps H.B. Fuller dependent on pricing, mix and restructuring savings to defend margins.
Raw materials add another pressure point. Nearly 90% of raw materials were higher sequentially in the second quarter, and more than 50 force majeure events remained in place.
H.B. Fuller and the AMS Risk Tradeoff
The Advanced Medical Solutions deal strengthens the long-term story. The proposed acquisition expands H.B. Fuller’s exposure to procedure-driven medical markets and could improve mix, growth and margins.
The deal is valued at about £715 million and is expected to add roughly $300 million in annual revenues. H.B. Fuller also targets about $55 million in annual revenue and cost synergies by 2031.
The tradeoff is leverage and execution. Pro forma net leverage is expected to be roughly 4X at close, with a target return to 2.5X-3X within two years.
FUL Scores Point to a Mixed Buy Case
The bottom line is that FUL screens attractively, but it is not a clean growth acceleration story. The stock’s value case rests on a low multiple, improving estimates and margin execution, while the risk case rests on volumes, inflation and acquisition leverage.
FUL currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
It also has a VGM Score of A, Value Score of A and Momentum Score of A, which supports the view that the stock has favorable value and sentiment characteristics.
The Growth Score of C keeps the signal balanced. For cautious investors, FUL looks more like a selective value opportunity than a no-risk bargain.